Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

DNA methylation alterations in grade II- and anaplastic pleomorphic xanthoastrocytoma

Authors: Ramón Martínez, F Javier Carmona, Miguel Vizoso, Veit Rohde, Matthias Kirsch, Gabriele Schackert, Santiago Ropero, Werner Paulus, Alonso Barrantes, Antonio Gomez, Manel Esteller

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Pleomorphic xanthoastrocytoma (PXA) is a rare WHO grade II tumor accounting for less than 1% of all astrocytomas. Malignant transformation into PXA with anaplastic features, is unusual and correlates with poorer outcome of the patients.

Methods

Using a DNA methylation custom array, we have quantified the DNA methylation level on the promoter sequence of 807 cancer-related genes of WHO grade II (n = 11) and III PXA (n = 2) and compared to normal brain tissue (n = 10) and glioblastoma (n = 87) samples. DNA methylation levels were further confirmed on independent samples by pyrosequencing of the promoter sequences.

Results

Increasing DNA promoter hypermethylation events were observed in anaplastic PXA as compared with grade II samples. We further validated differential hypermethylation of CD81, HCK, HOXA5, ASCL2 and TES on anaplastic PXA and grade II tumors. Moreover, these epigenetic alterations overlap those described in glioblastoma patients, suggesting common mechanisms of tumorigenesis.

Conclusions

Even taking into consideration the small size of our patient populations, our data strongly suggest that epigenome-wide profiling of PXA is a valuable tool to identify methylated genes, which may play a role in the malignant progression of PXA. These methylation alterations may provide useful biomarkers for decision-making in those patients with low-grade PXA displaying a high risk of malignant transformation.
Appendix
Available only for authorised users
Literature
1.
Kepes JJ, Rubinstein LJ, Eng LF: Pleomorphic xanthoastrocytoma: a distinctive meningocerebral glioma of young subjects with relatively favourable prognosis. A study of 12 cases. Cancer. 1979, 44: 1839-1852. 10.1002/1097-0142(197911)44:5<1839::AID-CNCR2820440543>3.0.CO;2-0.CrossRefPubMed
2.
Giannini C, Scheithauer BW: Classification and grading of low-grade astrocytic tumors in children. Brain Pathol. 1977, 7: 785-798.CrossRef
3.
Pahapill PA, Ramsay DA, Del Maestro RF: Pleomorphic xanthoastrocytoma: case report and analysis of the literature concerning the efficacy of resection and the significance of necrosis. Neurosurgery. 1996, 38: 822-828. 10.1227/00006123-199604000-00038.CrossRefPubMed
4.
Koeller KK, Henry J: From the archives of the AFIP: superficial gliomas: radiologic-pathologic correlation. Armed Forces Institute of Pathology. Radiographics. 2001, 21: 1533-1556. 10.1148/radiographics.21.6.g01nv051533.CrossRefPubMed
5.
Gil-Gouveia R, Cristino N, Farias JP, Trindade A, Ruivo NS, Pimentel J: Pleomorphic xanthoastrocytoma of the cerebellum: illustrated review. Acta Neurochir (Wien). 2004, 146: 1241-1244. 10.1007/s00701-004-0366-5.CrossRef
6.
Herpers MJ, Freling G, Beuls EA: Pleomorphic xanthoastrocytoma in the spinal cord. Case report. J Neurosurg. 2004, 80: 564-569.CrossRef
7.
Yeh DJ, Hessler RB, Stevens EA, Lee MR: Composite pleomorphic xanthoastrocytoma-ganglioglioma presenting as a suprasellar mass: case report. Neurosurgery. 2003, 52: 1465-1468. 10.1227/01.NEU.0000065138.24985.53.CrossRefPubMed
8.
Giannini C, Scheithauer BW, Burger PC, Brat DJ, Wollan PC, Lach B, O’Neill BP: Pleomorphic xanthoastrocytoma: what do we really know about it?. Cancer. 1999, 85: 2033-2045. 10.1002/(SICI)1097-0142(19990501)85:9<2033::AID-CNCR22>3.3.CO;2-Q.CrossRefPubMed
9.
Esteller M, Fraga MF, Paz MF, Campo E, Colomer D, Novo FJ, Calasanz MJ, Galm O, Guo M, Benitez J, Herman JG: Cancer epigenetics and methylation. Science. 2002, 297: 1807-1808.CrossRefPubMed
10.
Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002, 3: 415-487.CrossRefPubMed
11.
Esteller M: Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer. 2007, 96 (Suppl): R26-R30.PubMed
12.
13.
Cadieux B, Ching TT, Van den Berg SR, Costello JF: Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res. 2006, 66: 8469-8476. 10.1158/0008-5472.CAN-06-1547.CrossRefPubMed
14.
Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethylation profile of human cancer. Cancer Res. 2001, 61: 3225-3229.PubMed
15.
Waha A, Güntner S, Huang TH, Yan PS, Arslan B, Pietsch T, Wiestler OD, Waha A: Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas. Neoplasia. 2005, 7: 193-199. 10.1593/neo.04490.CrossRefPubMedPubMedCentral
16.
Horiguchi K, Tomizawa Y, Tosaka M, Ishiuchi S, Kurihara H, Mori M, Saito N: Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors. Oncogene. 2003, 22: 7862-7865. 10.1038/sj.onc.1207082.CrossRefPubMed
17.
Stone AR, Bobo W, Brat DJ, Devi NS, Van Meir EG, Vertino PM: Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am J Pathol. 2004, 165: 1151-1161. 10.1016/S0002-9440(10)63376-7.CrossRefPubMedPubMedCentral
18.
Nakamura M, Sakaki T, Hashimoto H, Nakase H, Ishida E, Shimada K, Konishi N: Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas. Cancer Res. 2001, 61: 6335-6339.PubMed
19.
Alaminos M, Dávalos V, Ropero S, Setién F, Paz MF, Herranz M, Fraga MF, Mora J, Cheung NK, Gerald WL, Esteller M: EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res. 2005, 65: 2565-2571. 10.1158/0008-5472.CAN-04-4283.CrossRefPubMed
20.
Tews B, Roerig P, Hartmann C, Hahn M, Felsberg J, Blaschke B, Sabel M, Kunitz A, Toedt G, Neben K, Benner A, von Deimling A, Reifenberger G, Lichter P: Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q. Oncogene. 2007, 26: 5010-5016. 10.1038/sj.onc.1210297.CrossRefPubMed
21.
Alonso ME, Bello MJ, Gonzalez-Gomez P, Arjona D, Lomas J, de Campos JM, Isla A, Sarasa JL, Rey JA: Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet. 2003, 144: 134-142. 10.1016/S0165-4608(02)00928-7.CrossRefPubMed
22.
Simpson DJ, Clayton RN, Farrell WE: Preferential loss of death associated Protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion. Oncogene. 2002, 21: 1217-1224. 10.1038/sj.onc.1205195.CrossRefPubMed
23.
Lindemann C, Hackmann O, Delic S, Schmidt N, Reifenberger G, Riemenschneider MJ: SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation. Acta Neuropathol. 2011, 122: 241-251. 10.1007/s00401-011-0832-0.CrossRefPubMed
24.
Laffaire J, Everhard S, Idbaih A, Criniere E, Marie Y, de Reynies A, Schiappa R, Mokhtari K, Hoang-Xuan K, Sanson M, Delattre JY, Thillet J, Ducray F: Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro Oncol. 2011, 13: 8498-CrossRef
25.
Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999, 59: 793-797.PubMed
26.
Martinez R, Schackert G, Yaya-Tur R, Rojas-Marcos I, Herman JG, Esteller M: Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. J Neurooncol. 2006, 83: 91-93.CrossRefPubMed
27.
Uhlmann K, Rohde K, Zeller C, Szymas J, Vogel S, Marczinek K, Thiel G, Nürnberg P, Laird PW: Distinct methylation profiles of glioma subtypes. Int J Cancer. 2003, 106: 52-59. 10.1002/ijc.11175.CrossRefPubMed
28.
Marucci G, Morandi L: Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma. J Neurooncol. 2011, 105: 397-400. 10.1007/s11060-011-0605-6.CrossRefPubMed
29.
Martinez R, Martin-Subero JI, Rohde V, Kirsch M, Alaminos M, Fernandez AF, Ropero S, Schackert G, Esteller M: A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics. 2009, 4: 255-264.CrossRefPubMed
30.
Carmona FJ, Villanueva A, Vidal A, Muñoz C, Puertas S, Penin RM, Gomà M, Lujambio A, Piulats JM, Mesía R, Sánchez-Céspedes M, Manós M, Condom E, Eccles SA, Esteller M: Epigenetic disruption of cadherin-11 in human cancer metastasis. J Pathol. 2012, 228: 230-240. 10.1002/path.4011.CrossRefPubMedPubMedCentral
31.
Rodríguez-Mena R, Joanes-Alepuz V, Barbella-Aponte R, Pérez-Valles A: Pleomorphic xanthoastrocytoma with intraventricular extension and anaplastic transformation in an adult patient: Case report. Neurocirugia (Astur). 2012, 23: 203-210. 10.1016/j.neucir.2011.08.003.CrossRef
32.
Ng WH, Lim T, Yeo TT: Pleomorphic xanthoastrocytoma in elderly patients may portend a poor prognosis. J Clin Neurosci. 2008, 15: 476-478. 10.1016/j.jocn.2006.09.012.CrossRefPubMed
33.
Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002, 61: 215-225.CrossRefPubMed
34.
Ohgaki H, Schäuble B, Zur Hausen A, Von Ammon K, Kleihues P: Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch. 1995, 427: 113-118.CrossRefPubMed
35.
Skiriute D, Vaitkiene P, Saferis V, Asmoniene V, Skauminas K, Deltuva VP, Tamasauskas A: MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma. BMC Cancer. 2012, 12: 218-10.1186/1471-2407-12-218.CrossRefPubMedPubMedCentral
36.
Skiriutė D, Vaitkienė P, Ašmonienė V, Steponaitis G, Deltuva VP, Tamašauskas A: Promoter methylation of AREG, HOXA11, hMLH1, NDRG2, NPTX2 and Tes genes in glioblastoma. J Neurooncol. 2013, 113: 441-449. 10.1007/s11060-013-1133-3.CrossRefPubMed
37.
Mueller W, Nutt CL, Ehrich M, Riemenschneider MJ, von Deimling A, van den Boom D, Louis DN: Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene. 2007, 26: 583-593. 10.1038/sj.onc.1209805.CrossRefPubMed
38.
Qiu H, Zhu J, Yuan C, Yan S, Yang Q, Kong B: Frequent hypermethylation and loss of heterozygosity of the testis derived transcript gene in ovarian cancer. Cancer Sci. 2010, 101: 1255-1260. 10.1111/j.1349-7006.2010.01497.x.CrossRefPubMed
39.
Weeks RJ, Kees UR, Song S, Morison IM: Silencing of TESTIN by dense biallelic promoter methylation is the most common molecular event in childhood acute lymphoblastic leukaemia. Mol Cancer. 2010, 9: 163-10.1186/1476-4598-9-163.CrossRefPubMedPubMedCentral
40.
de Sousa E, Melo F, Colak S, Buikhuisen J, Koster J, Cameron K, de Jong JH, Tuynman JB, Prasetyanti PR, Fessler E, van den Bergh SP, Rodermond H, Dekker E, van der Loos CM, Pals ST, van de Vijver MJ, Versteeg R, Richel DJ, Vermeulen L, Medema JP: Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell. 2011, 9: 476-485. 10.1016/j.stem.2011.10.008.CrossRef
41.
Küry P, Greiner-Petter R, Cornely C, Jürgens T, Müller HW: Mammalian achaete scute homolog 2 is expressed in the adult sciatic nerve and regulates the expression of Krox24, Mob-1, CXCR4, and p57kip2 in Schwann cells. J Neurosci. 2012, 22: 7586-7595.
42.
Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R: Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004, 10: 1871-1874. 10.1158/1078-0432.CCR-03-0384.CrossRefPubMed
43.
Sallinen SL, Sallinen P, Haapasalo H, Kononen J, Karhu R, Helén P, Isola J: Accumulation of genetic changes is associated with poor prognosis in grade II astrocytomas. Am J Pathol. 1997, 151: 1799-1807.PubMedPubMedCentral
44.
Rey JA, Bello MJ, de Campos JM, Kusak ME, Moreno S: Chromosomal composition of a series of 22 human low-grade gliomas. Cancer Genet Cytogenet. 1987, 29: 223-237. 10.1016/0165-4608(87)90233-0.CrossRefPubMed
45.
Yin XL, Hui AB, Liong EC, Ding M, Chang AR, Ng HK: Genetic imbalances in pleomorphic xanthoastrocytoma detected by comparative genomic hybridization and literature review. Cancer Genet Cytogenet. 2002, 132: 14-19. 10.1016/S0165-4608(01)00512-X.CrossRefPubMed
46.
Weber RG, Hoischen A, Ehrler M, Zipper P, Kaulich K, Blaschke B, Becker AJ, Weber-Mangal S, Jauch A, Radlwimmer B, Schramm J, Wiestler OD, Lichter P, Reifenberger G: Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas. Oncogene. 2007, 26: 1088-1097. 10.1038/sj.onc.1209851.CrossRefPubMed
47.
Grau E, Balaguer J, Canete A, Martinez F, Orellana C, Oltra S, Hernandez M, Castel V: Subtelomeric analysis of pediatric astrocytoma: subchromosomal instability is a distinctive feature of pleomorphic xanthoastrocytoma. J Neurooncol. 2007, 93: 175-182.CrossRef
48.
Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A: Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011, 121: 397-405. 10.1007/s00401-011-0802-6.CrossRefPubMed
49.
Rodríguez-Paredes M, Esteller M: Cancer epigenetics reaches mainstream oncology. Nat Med. 2010, 17: 330-339.
50.
Carmona FJ, Esteller M: DNA methylation in early neoplasia. Cancer Biomark. 2011, 9: 101-111.
51.
Martinez R, Setien F, Voelter C, Casado S, Quesada MP, Schackert G, Esteller M: CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. Carcinogenesis. 2007, 28: 1264-1268. 10.1093/carcin/bgm014.CrossRefPubMed
Metadata
Title
DNA methylation alterations in grade II- and anaplastic pleomorphic xanthoastrocytoma
Authors
Ramón Martínez
F Javier Carmona
Miguel Vizoso
Veit Rohde
Matthias Kirsch
Gabriele Schackert
Santiago Ropero
Werner Paulus
Alonso Barrantes
Antonio Gomez
Manel Esteller
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-213

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Excess visceral adiposity induces alterations in mitochondrial function and energy metabolism in esophageal adenocarcinoma

Research article

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy

Research article

High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients

Research article

Ethnic differences in timely adjuvant chemotherapy and radiation therapy for breast cancer in New Zealand: a cohort study

Research article

Care provided and care setting transitions in the last three months of life of cancer patients: a nationwide monitoring study in four European countries

Research article

Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits